Smoking cessation

Stephen I Rennard; David M Daughton

doi:10.1016/j.ccm.2013.11.002

Smoking cessation

Clin Chest Med. 2014 Mar;35(1):165-76. doi: 10.1016/j.ccm.2013.11.002.

Authors

Stephen I Rennard¹, David M Daughton²

Affiliations

¹ Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, 985910 Nebraska Medical Center, Omaha, Nebraska 68198-5910, USA. Electronic address: srennard@unmc.edu.
² Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, 985910 Nebraska Medical Center, Omaha, Nebraska 68198-5910, USA.

PMID: 24507844
DOI: 10.1016/j.ccm.2013.11.002

Abstract

Cigarette smoking is a major preventable cause of morbidity and mortality. It is the major risk factor for chronic obstructive pulmonary disease in the developed world. Smoking is a chronic relapsing disease. Optimal treatment includes nonpharmacologic support, together with pharmacotherapy. All clinicians should be comfortable with the use of nicotine replacement therapy, bupropion, and varenicline. Second-line therapies can be used by those familiar with their use. Effective use of these medications requires their integration into an effective management plan, which is likely to be a long-term undertaking, involving several cycles of remission and relapse.

Keywords: Cessation; Pharmacotherapy; Smoking; Treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Benzazepines / therapeutic use
Bupropion / therapeutic use
Dopamine Uptake Inhibitors / therapeutic use
Humans
Nicotine / metabolism
Nicotinic Agonists / therapeutic use
Pulmonary Disease, Chronic Obstructive / therapy*
Quinoxalines / therapeutic use
Smoking / drug therapy*
Smoking / physiopathology
Smoking Cessation / methods*
Tobacco Use Cessation Devices*
Varenicline

Substances

Benzazepines
Dopamine Uptake Inhibitors
Nicotinic Agonists
Quinoxalines
Bupropion
Nicotine
Varenicline